Saturday, November 7, 2015

FTC says FDA's biosimilar drug naming plan would hurt competition ModernHealthcare.com-17 hours ago The naming issue will be particularly important when some biosimilar products eventually receive FDA approval for interchangeability, meaning that pharmacists

No comments: